Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ADH5 | P11766 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12796748 | 0.84 | NPC1 (0.45) | SMN1; SMN2RAB9AMAPTKMT2ATP53 | |
| SCHEMBL14172586 | 0.81 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2RAB9AMAPTKDM4E | |
| SCHEMBL14172538 | 0.81 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2RAB9AMAPTKDM4E | |
| SCHEMBL14172595 | 0.80 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2RAB9AMAPTKDM4E | |
| SCHEMBL14172531 | 0.80 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2RAB9AMAPTKDM4E | |
| SCHEMBL14172575 | 0.79 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2RAB9AMAPTKDM4E | |
| SCHEMBL12848563 | 0.78 | ADH5 (0.36) | ROCK2MAPTABL1ADH5 | |
| SCHEMBL14172587 | 0.78 | IL2 (0.47) | ALDH1A1SMN1; SMN2RAB9AMAPTKDM4E | |
| SCHEMBL14172764 | 0.77 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2RAB9AMAPTKDM4E | |
| SCHEMBL12796210 | 0.77 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2RAB9AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779154-B2 | Fused ring compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2014-07-15 | — | — | US | disclosed |
| US-8779154-B2 | Fused ring compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2014-07-15 | — | — | US | disclosed |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2009089305-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20080132513-A1 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132513-A1 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2008039520-A2 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132513-A1 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NOD2, RORC, NLRP3 | ROCK2 3314/4885ALDH1A1 2365/4885SMN1; SMN2 4866/4885 |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | ROCK2 1732/4885ALDH1A1 644/4885SMN1; SMN2 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.